

ANTARES project launch: Artificial Intelligence aims to speed up the search for new antibacterials

FRANKFURT AM MAIN, GERMANY, July 23, 2026 /EINPresswire.com/ -- ANTARES is a new public-private partnership funded by the German Federal Ministry of Research, Technology and Space (BMFTR) that brings together the Fraunhofer ITMP in Hamburg, the Helmholtz Centre for Infection Research (HZI) in Braunschweig and Enamine Deutschland GmbH from Frankfurt am Main (Enamine). The partners will use AI models to rapidly identify novel antibiotics towards safer, more affordable cures for patients battling life-threatening and often drug-resistant infections.

The AI models will be trained and tested using publicly available datasets, providing a low-risk approach to optimize the most suitable model. After the initial adjustment, the model is improved iteratively using high throughput testing of substances predicted to be antibacterially active to achieve the best possible prediction accuracy. In order to enhance the discrimination power of the model, structurally similar compounds that were predicted to be inactive will also be confirmed experimentally in addition to the hits. “Das ANTARES-Projekt ist ein wichtiger Schritt in der Entwicklung neuer Antibiotika. Durch die Zusammenarbeit von Fraunhofer ITMP, HZI und Enamine werden wir in der Lage sein, neue Wirkstoffe zu identifizieren, die wir dann in klinischen Studien testen können. Das Projekt ist ein Beispiel für die erfolgreiche Zusammenarbeit zwischen Wissenschaft und Industrie.”



Fraunhofer-Institut für
Translationale Medizin und
Pharmakologie ITMP

HZI HELMHOLTZ
Zentrum für Infektionsforschung



explains Dr. Bernhard Ellinger from Fraunhofer ITMP. Importantly, while starting with known datasets the consortium has the ability to make and test newly synthesized libraries.

0000000000 00000000 00000 0000-0000000000 0000000000000000

The three partners of ANTARES, Fraunhofer ITMP, HZI and Enamine, are all experts in translating their respective scientific expertise into inventions and products.

[illegible]

To enable this vision, structure-activity relationships learned from the models will be extracted using ExplainableAI (XAI) approaches. In addition, a generative model will propose new structures with antibiotic activity. The models and the developed standardized data sets will be published FAIR to support further antibiotic drug discovery. “**Das ist ein Meilenstein für die Entwicklung neuer Antibiotika**, da wir nun in der Lage sind, die Wirkmechanismen von Antibiotika zu verstehen und diese gezielt zu optimieren“, erklärt Prof. Dr. Frank Hees vom Helmholtz Institut für Pharmazie und Experimentelle Medizin (HIM). „Dieser Schritt ist entscheidend für die Entwicklung neuer Medikamente, die gegen resistente Bakterien wirken.“

0300001860.

Fact box

Projekttitel: Antibiotic Network for Targeted AI-driven Research and Explainable Screening

Acronym: ANTARES

Projektbeginn: 01.07.2026

Projektlaufzeit: 3 Jahre

Fördersumme: 1,18 Millionen €

Zuwendungsgeber: Bundesministerium für Forschung, Technologie und Raumfahrt

Projektträger: PtJ Projektträger Jülich

Enamine

Enamine is the leading provider of chemical compounds and a scientifically driven Contract Research Organisation for integrated drug discovery (IDD) with unique partnering opportunities in exploring new chemical spaces. The company combines access to the in-house produced screening compounds (5 million in stock) and building blocks (350,000 in stock) with a comprehensive platform of integrated discovery services in bioinformatics, biology, and chemistry to advance and accelerate the efforts in drug discovery.

For more information, please visit: <https://enamine.net/>

Oleksii Gavrylenko

Director of Marketing

Oleksii Gavrylenko

Director of Marketing

Email: o.gavrylenko@enamine.net

Fraunhofer ITMP

Fraunhofer ITMP with its Hamburg site has a strong expertise in high-throughput drug discovery using high-quality compound and repurposing libraries (in silico and in vitro screening). We are also developing workflows to ensure the analysis of drug discovery data and the highest standards of FAIR data management, as well as algorithms and AI tools for the statistical analysis of patient cohorts in different medical indications, thus covering the broad field of »medical data science«.

For more information, please visit: <https://www.itmp.fraunhofer.de/>

Dr. Alena Wötzel

Dr. Alena Wötzel

Head of Public Relations

Email: alena.woetzel@itmp.fraunhofer.de

Scientists

Scientists at the Helmholtz Centre for Infection Research (HZI) in Braunschweig and its other sites in Germany are engaged in the study of bacterial and viral infections and the body's

defense mechanisms. They have a profound expertise in natural compound research and its exploitation as a valuable source for novel anti-infectives. As member of the Helmholtz Association and the German Center for Infection Research (DZIF) the HZI performs translational research laying the ground for the development of new treatments and vaccines against infectious diseases.

For more information, please visit: <https://www.helmholtz-hzi.de/>

Oleksii Gavrylenko

Enamine Ltd

[email us here](#)

Visit us on social media:

[LinkedIn](#)

[Instagram](#)

[Facebook](#)

[X](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/928591222>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2026 Newsmatics Inc. All Right Reserved.